Makita Shinichi, Tobinai Kensei
Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Hematol Oncol Clin North Am. 2017 Apr;31(2):239-253. doi: 10.1016/j.hoc.2016.11.007. Epub 2017 Jan 30.
Extranodal natural killer/T-cell lymphoma, nasal type (ENKL), is a rare subtype of non-Hodgkin lymphoma, and its treatment outcome was previously poor. Novel treatment strategies have improved the outcomes of ENKL remarkably in the last decade. Nowadays, patients with localized nasal ENKL are recommended treatment with concurrent chemoradiotherapy, and their 5-year overall survival rate is approximately 70%. In patients with advanced or relapsed/refractory disease, the efficacy of l-asparaginase-containing therapy has been confirmed. However, there still remain unmet needs in the treatment of ENKL. Continued efforts should be made to further improvements in the treatment of ENKL.
结外鼻型自然杀伤/T细胞淋巴瘤（ENKL）是一种罕见的非霍奇金淋巴瘤亚型，其治疗效果此前较差。在过去十年中，新的治疗策略显著改善了ENKL的治疗效果。如今，局限性鼻型ENKL患者推荐采用同步放化疗，其5年总生存率约为70%。在晚期或复发/难治性疾病患者中，含L-天冬酰胺酶治疗的疗效已得到证实。然而，ENKL的治疗仍存在未满足的需求。应继续努力进一步改善ENKL的治疗。
